What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 1, Pre-Registered Trial).

December 8, 2025Blood

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

View Full Paper

Ask AI

Bookmark

Authors

Phase 1 trial shows CAR T cells led to 100% complete response in relapsed B-cell lymphomas, suggesting effective new therapy options.

Complete response achieved in 100% of patients treated with BAFFR-CAR T cells for relapsed B-cell lymphomas during the trial.
Minimal residual disease testing confirmed high efficacy with robust cell expansion post treatment in multiple patients.
Phase 1 trial assessed safety, with no significant adverse events recorded; favorable outcomes may direct future therapy options.
Durable responses up to 32 months indicate potential impact of BAFFR-CAR T cells in managing difficult B-cell malignancies.],

Budde et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Phase 1 trial shows CAR T cells led to 100% complete response in relapsed B-cell lymphomas, suggesting effective new therapy options.

Complete response achieved in 100% of patients treated with BAFFR-CAR T cells for relapsed B-cell lymphomas during the trial.
Minimal residual disease testing confirmed high efficacy with robust cell expansion post treatment in multiple patients.
Phase 1 trial assessed safety, with no significant adverse events recorded; favorable outcomes may direct future therapy options.
Durable responses up to 32 months indicate potential impact of BAFFR-CAR T cells in managing difficult B-cell malignancies.],

Budde et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark